Key facts
- This page summarizes Carol Y. Suh's Form 4 filing for Neumora Therapeutics, Inc. (NMRA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Feb 2024, 16:19.
Carol Y. Suh - 14 Feb 2024 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- NMRA
- Reported as of
- 14 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Feb 2024, 16:19:21 UTC
- Prior SEC filing
- 14 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joshua Pinto, as Attorney-in-Fact for Carol Y. Suh
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Carol Y. Suh filed Form 4 for Neumora Therapeutics, Inc. (NMRA) on 16 Feb 2024.
Change
- Previous filing in this sequence was filed on 14 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NMRA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +85,000
- Change %
- +29%
- Price
- $0.000000
- Shares after
- 374,674
- Date
- 14 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NMRA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +170,000
- Change %
- Price
- $0.000000
- Shares after
- 170,000
- Date
- 14 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 170,000
- Exercise price
- $18.07
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
Footnote F2
25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.